Curriculum Vitae selected

Name and surname :

Farhad Zaker

Academic title:

Professor of haematology

Assistant head of department of Haematology and Blood Banking at Iran University Medical Sciences

Qualifications:

PhD in ″Haematology″ in 1997 from University of Wales, College of medicine, Cardiff-UK

Education andTeaching:

Teaching of Haematology, Immunohaematology, cell culture, molecular medicine to medica and allied medical students (theoretical and practical) in different levels (undergraduate and post graduate students)

Research activities:

A-Involvement in many student project, Thesis and research projects

B-Books:

-Zaker F and Ghanizadeh S.transcription factors in normal haematopoiesis and leukaemia. Khosravi press, 2013.

-Zaker F and sharifi MJ. Review of haematology.and diseases, Farda press, 2011.

-Zaker F and Niazpour M. Principle of hemostasis and disease. Kamal Danesh press, 2006.

C-International Paper Publications:

-Naderi M, , Alizadeh S, kazemi A, Tabibian S, **zaker f**, Bamedi T, Kashani Khatib Z, , Dorgalaleh. Central nervos system bleeding in pediatric patients with factor XIII def. A study on 23 new cases , Hematology , 2015, 20 (2), 112-118.

-Naderi M, Tabibian S, Dorgalaleh A, Alizadeh S, **Zaker F (correspond**), Bamedi T. Congenital factor V def, comparison the severity of clinical presentations among patients with rare bleeding disordersActa Hematol, 2014, 26:133 (2), 148-154 .

-Nasiri N,Shiekhi M, **Zaker F (correspond),** Hosseini S, Moosavi S A, Marjani A .Diagnosis and biological characteristic of FLT3 mutations in AML. AIM, 2014, 17 (4), 258-261.

-Ostadebrahimi H, Jamali Z, Nazari M, Bahri M, Farahmandnia Z, Khandany BK, Taheri M, Khorramdelazad H, Hakimizadeh E, **Zaker F,** Rezaeian M, Hassanshahi G. CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 are variably expressed in patients with sickle cell disease and carriers: are they predictive tools for disease complication. Clin Lab. 2014;60(1):99-104.

-Sharifi MJ, Bahosh G, **Zaker F(correspond**), Ansari S, Arjmandi Rafsanjani K and Sharafi H. Association of 24 CT, 1249GA, and 3972 CT gene polymorphisms with Methotrexate serum levels and toxic side effects in children with acute lymphiblastic leukaemia, .Pediatric Hematology Oncology, 2014, . 31 (2), 169-177

-Rahnemoon AR, **Zaker F**, Izadyar M, Ansari S, Poopak B, Tadavosyan Y. Prevalence of ETV6/RUNX1 Fusion Gene in Pediatric Patients with Acute Lymphoblastic Leukemia in Iran. Int J Ped, 2013 Dec;23(6):681-6

-Tahmasbi MH, Joghataei MT, Soleimani M, Moosavi SA, Yazdanparast SA, **Zaker F**. 3D study of capillary network derived from human cord mesenchymal endothelial stem cells have differentiated into endothelial cells with VEGFR2 protein expression. Res Mol Med, 2013, 1(2), 17-21.

-Bashash D, Ghafari SH, **Zaker f** et al. BIBR 1532 increases arsenic trioxide – mediated apoptosis in acute promyelocytic leukaemia cells: therapeutic potential for APL. Anticancer Agents Med Chem, 2013 , 13 (7), 1115-1125 .

-Hassani s, Ghafari SH, **Zaker f** , zekri a,alimoghaddam k, qhavamzadeh a, zaghl a, azidothymidine hinders arsenic trioxide induced apoptosis in apl cells via ineraction of p21 and attenuation of G2/M arrest. Ann Hem, 2013, 92 (9), 1207-1220.

- Chahardouli B, , Mousavi SA, **Zaker F** , Saffari Z, Ostadi M, Nadali F, Ghadimi H, Rostami S, Alimoghaddam K, Ghavamzadeh A. detection of bcr-abl kinase domain mutations in patients with cml on imatinib . Haematology, 2013, 18 (6):328-333.

-Chahardoouli B, **zaker f**, mousavi sa, kazemi A, ostadi m, rostami s, ghavamzadeh a. evaluation of T315I mutation frequency in CML patients after Imatinib resistanc., haematology,2013 (18 (3). 158-162.

-**Zaker f,** Nasiri N,Amirizadeh N, Oodi A. Evaluation of umbilical cord blood $CD34^+$ hematopoietic stem cells expansion in co-culture with BM mesenchymal stem cells in the presence of Cu chelator TEPA .Haematology, 2013, 18 (1), 39-45.

-Soltanpour MS, Amirizadeh N, **Zaker F**, Oodi A, Nikougoftar M. , Kazemi A. mRNA expression and promoter DNA methylation status of CDKi p21 and p57 genes in ex vivo expanded CD 34 cells following co-culture with mesenchymal stromal cells and promoter growth factors. Haematology, 2013, 18(1), 30-38.

-Safaei A and **Zaker F**. Influence of genetic abnormality on the risk of ALL. Iranian J Blood and Cancer. 2012, 4(4), 169-178.

-**Zaker F(correspond**), Safaei A, Nasisr N, Abdollahzadeh M and Pazhakh V (2012). The association of NADPH : quinine oxireductase gene polymorphisms with pediatric ALL . LabMedicine, 43, 256-261.

-Bakhshayesh M, **Zaker F** ,Hashemi M ,Katebi M, Solaimani M ,(2012). TGF-B1 mediated Apoptosis is associated to SMAD dependent Mitochondrial Bcl-2 expression. Clinical lymphoma leukemia. 12 (2), 138-143.

-Shirafkan A, Marjani A and **Zaker F.** (2012) Serum lipid profiles in acute myocardial infarction patients in Gorgan. Biomedical Research, 23 (1), 119-124.

-Bashash D, Ghafari SH, **Zaker f** et al. (2012) Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukaemia cells through induction of p21 coupled with downregulation of c-myc snd htert transcription. Cancer Investigation.30 (1), 57-64.

-**Zaker F(correspond),** Safaei A Hashemi M and Pazhakh V (2011). The frequency and association of C609T and C465T Polymorphisms of NADPH : quinine oxireductase gene with adult AML. LabMedicine, 42 (11), 674-677.

-Safa M , Kazemi A, **Zaker F** et al. (2011). Cyclic AMP induced p53 destabilisation is dependent of EPAC in pre B ALL in vitro. Journal of receptors and signal transductions. 31 (3), 256-263.

-Atashrazm F and **Zaker F (correspond)** et al. (2011) Polymorhysms of MTHFR and susceptibility to ALL in children. LabMedicine, 42(5), 275-279.

-Razmkha F, Pazhakh V, **Zaker F (correspond),** Atashrazm F and Sheikhi M (2011). Frequency of Cyp1A1*2C in patients with leukemia in the Iranian population. Lab medicine, 42 (4), 220-223.

-Pazhakh V , **Zaker F (correspond)** et al (2011). detection of nucleophosmin and fms-like tyrosine kinase 3 gene mutations in AML patients. Ann Saudi Med, 31(1),45-50.

-Razmkhah f, Razavi m, , **zaker f,** et al (2010): hematologic and molecular responses to generic immatinib in patients with CML. LabMedicine, 41 (9), 547-550.

-Pazhakh V, Razmkhah F, **Zaker F(correspond)** et al (2010). MTHFR and risk of myeloid leukaemia. LabMedicine, 41 (8), 490-494.

-Safa M, Kazemi A, Zand H, Azarkeivan A, **Zaker F,** Hayat P (2010) Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre B ALL cell through dephosphorylation of p53 serine residues. Apoptosis. 15 (2), 196-203.

-**Zaker F (correspond)** et al. Detection of kit and flt3 mutation in AML with different subtypes. Archives of Iranian Medicine.2010 13 (1),21-25.

-**Zaker F (correspond),** Oody A and Arjmand AR (2007) A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukemic cells. Arch Pharm Res. 30 (7), 844-849

-Mohsenifar A, Lotfi A S, Ranjbar B, Allameh A , **Zaker F** et al . (2007). A study of the oxidation induced conformational and functional changes in neuroserpin. Iranian Biomedical J. 11(1), 41-46.

-Ardjmand AR, **Zaker F(correspond),** Alimoghadam K and Moezzi L (2006). Arsenic Trioxide selectively induces apoptosis within the leukemic cells of APL patients. Int.J.Pharm 2(4): 459-462.

-Ardjmand AR, , Alimoghadam K , **Zaker F** and Ghavamzadeh A, Jahani M (2004). Arsenic Trioxide selectively induces apoptosis within the leukemic cells of APL patients with T(15-17) possibly through the FAS pathway. IJHOBMT 1(2):20-24 .

-**Zaker F (correspond),** May A and Burnett A K (2002) Key regulatory gene expression in erythroleukaemia differentiation. Iranian Biomedical journal 6 (4), 97-103.

-**Zaker F,** Darley R L, Al-Sabah A I and Burnett A K (1997) Oncogenic ras genes impair erythroid differentiation of erythroleukaemia cells. Leukaemia Research 21 (7), 635-640.

D-Presentation (oral and poster): Over 50 presentation in international congress with abstract

Patents:

-Documentation of Kit mutations in Gene Bank including FJ189474 and FJ177639

- Documentation of bcr-abl mutations in Gene Bank jx565024 and jx565025

Academic Responsibility:

-Member of haematology board in Ministry of Health and Medical education of Iran

-Cooperation in establishment of MSC and PhD course of haematology and Blood Banking

-Member of scientific committee of Cellular and Molecular Research Center, Molecular Medicine department

-Member of of scientific committee of several journals

-Member of some Scientific society, transfusion society of iran , lab sciences of iran and abroad such as (EHA, ISH, ISEH , IACSIT etc).

Membership:

1) Member of scientific committee of Cellular and Molecular Research Center (CMRC) at university

2) Member of scientific committee of Oncopathology research Center at university

3) Member of Molecular Medicine department at university

4) Member of scientific committee of several Iranian and abroad journals

5) Member of some Scientific society, transfusion society of iran , lab sciences of iran and abroad such as (EHA, ISH, ISEH , IACSIT etc).

6) Member of Modern Technology Faculty –regenerative medicine and cell therapy